Silverman, S., Curtis, J., Saag, K., Flahive, J., Adachi, J., Anderson, F., Chapurlat, R., Cooper, C., Diez-Perez, A., Greenspan, S., Hooven, F., Le Croix, A., March, L, Netelenbos, J.C., Nieves, J., Pfeilschifter, J., Rossini, M., Roux, C., Siris, E., Watts, N. and Compston, J. (2015) International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporosis International, 26 (1), 419-420. (doi:10.1007/s00198-014-2883-2.). (PMID:25257932)
Abstract
We used the GLOW database to study the bone health management postmenopausal women with glucocorticoid exposure. GLOW is a 5-year observational study of 60,000 postmenopausal women enrolled in 17 sites in 10 countries in Europe, North America, and Australia. We studied the use of BMD testing within the past 3 years of the study and medical management in glucocorticoid-exposed individuals during the third year of survey in GLOW.
Of the 40,058 women with complete data over the 5 years, 893 (2 %) reported continuous use of glucocorticoids over the past 2 or more years at the 3-year survey and 29,080 (73 %) were nonusers. Our study demonstrated considerable differences in BMD management in glucocorticoid users by site and region (see Table 1). Glucocorticoid-exposed individuals had greater use of BMD testing and medical management than nonusers, although the number of individuals remained low (?51 %) worldwide in current continuous users. The proportion of individuals with current continuou ...
This record has no associated files available for download.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.